Literature DB >> 19686824

Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes.

Petr Bachleda1, Radim Vrzal, Jakub Pivnicka, Boris Cvek, Zdenek Dvorak.   

Abstract

A hypnotic drug Zolpidem is used in clinical practice for more than 25 years. Surprisingly, the effects of Zolpidem on the expression of drug-metabolizing cytochromes P450 (CYPs) were not examined yet. Recently, the unexpected capacity of several "old drugs", such as valproic acid or azoles, to induce CYPs was reported. Therefore, we tested whether Zolpidem induces the expression of important CYPs in primary cultures of human hepatocytes. Cells were treated for 24h with Zolpidem in therapeutic (0.1mg/L) and toxic (1mg/L) concentrations. The levels of CYP1A1, CYP1A2, CY2C9 and CYP3A4 mRNAs were not altered by Zolpidem, whereas model inducers dioxin and rifampicin significantly induced CYP1A and CYP2/3 gene expression, respectively. Consistently, Zolpidem did not activate aryl hydrocarbon receptor (AhR) and pregnane X receptor (PXR), the key regulators of cytochromes P450s, as revealed by transient transfection gene reporter assays using HepG2 cells. We conclude Zolpidem be considered a safe drug with respect to the possible interactions through AhR- and PXR-dependent induction of drug-metabolizing CYPs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19686824     DOI: 10.1016/j.toxlet.2009.08.009

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  2 in total

1.  Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene.

Authors:  Lucie Krausova; Lucie Stejskalova; Hongwei Wang; Radim Vrzal; Zdenek Dvorak; Sridhar Mani; Petr Pavek
Journal:  Biochem Pharmacol       Date:  2011-09-06       Impact factor: 5.858

2.  Rifampicin Does not Significantly Affect the Expression of Small Heterodimer Partner in Primary Human Hepatocytes.

Authors:  Petr Pavek; Lucie Stejskalova; Lucie Krausova; Michal Bitman; Radim Vrzal; Zdenek Dvorak
Journal:  Front Pharmacol       Date:  2012-01-19       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.